Aratana Therapeutics Inc (NASDAQ:PETX) shares were falling nearly 18% on the heels of Friday’s announcement revealing that Entyce, approved in the U.S.
Post-operative pain drug Nocita expected to begin generating widespread sales, says William Blair
In a research report issued today, William Blair analyst John Kreger reiterated an Outperform rating on IMS Health Holdings (NYSE:IMS). No price target …
In a research report issued today, William Blair analyst John Kreger assigned an Outperform rating on Aratana Therapeutics (NASDAQ:PETX), following the company’s public …
In a research report issued yesterday, William Blair analyst John Kreger maintained an Outperform rating on Aratana Therapeutics (NASDAQ:PETX), following yesterday’s news that …
In a research report issued yesterday, William Blair analyst John Kreger reiterated an Outperform rating on Quintiles Transnational Holdings (NYSE:Q), following the company’s …
In a research report issued today, William Blair analyst John Kreger reiterated an Outperform rating on Zoetis (NYSE:ZTS). No price target was provided.
In a research note published yesterday, William Blair analyst John Kreger maintained an Outperform rating on Cardinal Health (CAH) following the company’s release of …
